Have any questions? [email protected] +86-21-58998590
Structure search

Benralizumab (anti-IL5RA )


CAS No. : 1044511-01-4

(Synonyms: MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA ))

1044511-01-4
Price and Availability of CAS No. : 1044511-01-4
Size Price Stock
1mg $650 In-stock
5mg $1800 In-stock
10mg $2800 In-stock
50 mg Get quote
100 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-P9923A
M.Wt: 1000.00
Formula: N/A
Purity: >98 %
Solubility: 10 mM in DMSO
Introduction of 1044511-01-4 :

Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study [1][2]. IC50 & Target:IL-5Ra/ CD125 In Vitro:Benralizumab (MEDI-563) binds to recombinant human and cynomolgus monkey IL-5Rα extracellular domains with a dissociation constant of 11 and 42 pM, respectively[2].
Benralizumab (1 pM-100 nM, 48 h) inhibits IL-5–induced proliferation of CTLL-2 cells transfected with recombinant human IL-5Rαβ with an IC50 of 0.3 nM[2].
Benralizumab binds only to the constructs containing human IL-5Rα D1[2].
Benralizumab mediates ADCC (antibody-dependent cell-mediated cytotoxicity) of human eosinophils and basophils with EC50s of 0.9 pM and 0.5 pM, respectively, and mediates eosinophil apoptosis[2]. In Vivo:Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil[2].

Your information is safe with us.